miR-142 is also mutated in approximately 20% of DLBCL cases, where mutations in the seed region lead to a loss of binding activity to oncogenic RAC1 and ADCY9 mRNA transcripts and a possible gain of binding activity to transcriptional repressors ZEB1 and ZEB2 [42]. The gene discussed is RAC1; the disease is diffuse large B-cell lymphoma.